The metric biotech gets wrong: burn quality
Runway is a vanity metric. Risk removed per euro is the point.
Runway is comforting. Conviction is what closes.
Investors care less about months of cash than about how much doubt each tranche destroys. High‑quality burn creates decision gates, improves negotiating power, and clarifies the clinical direction. Replace activity with risk retired per €.
What to do Monday
- Replace "18 months runway" with a 12‑month gate‑by‑gate map of pivotal uncertainties and the experiments that collapse them.
- Score each planned spend: does it move a gate, clarify the story, or increase belief? Cut what doesn't.
- Report risk eliminated alongside cash burn each quarter.
The companies that raise fastest don't just burn cash efficiently-they burn uncertainty systematically.
Most biotech companies track burn rate like it's the primary metric. "We have 18 months of runway" feels reassuring, but it tells investors nothing about what you'll prove in those 18 months. The sophisticated money asks different questions: Which risks will you retire? What decisions will you enable? How will you improve your negotiating position?
Like what you're reading?
Subscribe for more strategic notes on biotech and venture design.
High-quality burn has three characteristics: it creates decision gates (clear moments where you'll know if the approach works), it improves strategic position (better terms in partnerships, clearer regulatory path, stronger IP), and it generates external validation (KOL endorsement, regulatory feedback, pharma interest).
This means designing experiments for conviction, not just data. Instead of "validate mechanism," aim for "prove mechanism sufficiently to trigger pharma BD interest." Instead of "advance lead compound," aim for "generate data package that supports IND filing." The difference is specificity about what changeswhen the experiment succeeds.
The best companies also build burn quality reviews into their quarterly cadence. Each spend gets scored: Does this move us through a decision gate? Does this clarify the investment story? Does this increase our negotiating power? Anything that scores low gets cut or redesigned.
Where this tends to sit: quarterly cadence & OKRs (Fractional CIO) and the first 2–4‑week investor‑readiness pass that produces the milestone ladder.
Investors don't fund activities; they fund value inflection points. Let's align your next round's ask with a strategic capital allocation plan.
Structure your capital strategy